Evidence for the Positive Impact of Centralization in Esophageal Cancer Surgery.


Journal

Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354

Informations de publication

Date de publication:
13 Aug 2024
Historique:
medline: 14 8 2024
pubmed: 14 8 2024
entrez: 14 8 2024
Statut: aheadofprint

Résumé

In this study we analyzed the impact of centralization on key metrics, outcomes and patterns of care at the Irish National Center. Overall survival rates in esophageal cancer in the West have doubled in the last 25 years. An international trend towards centralization may be relevant, however this model remains controversial with Ireland, centralizing esophageal cancer surgery in 2011. All patients (n=1245) with adenocarcinoma of the esophagus or junction treated with curative intent involving surgery, including endoscopic surgery, were included (n= 461 from 2000-2011, and 784 from 2012-2022). All data entry was prospectively recorded. Overall survival was measured (i) for the entire cohort; (ii) patients with locally advanced disease (cT2-3N0-3); and (iii) patients undergoing neoadjuvant therapy. All complications were recorded as per Esophageal Complication Consensus Group (ECCG) definitions, and the Clavien Dindo (CD) severity classification. Data were analyzed using GraphPad Prism (v.6.0) for Windows and SPSS (v.23.0) software (SPSS,Chicago,IL) RStudio (Rversion4.2.2). Survival times were calculated using log-rank test and a Cox-regression analysis, and Kaplan-Meier curves generated. Endotherapy for cT1a/IMC adenocarcinoma increased from 40 (9% total) to 245 (31% total) procedures between the pre-centralization (pre-C) and post-centralization (post-C) periods. A significantly (P<0.001) higher proportion of patients with cT2-3N0-3 disease in the post-C period underwent neoadjuvant therapy (66% vs 53%). Operative mortality was lower (P=0.02) post-C, at 2% vs 4.5%, and>IIIa CD major complications decreased from 33% to 25% (P<0.01). Recurrence rates were lower post-C (38% vs 53%, P<0.01). Median overall survival was 73.83 versus 47.23 months in the 2012-22 and 2000-11 cohorts respectively (P<0.001). For those who received neoadjuvant therapy, the median survival was 28.5 months pre-C and 42.5 months post-C (P<0.001). These data highlight improvements in both operative outcomes and survival from the time of centralization, and a major expansion of endoscopic surgery. Although not providing proof, the study suggests a positive impact of formal centralization with governance on key quality metrics, and an evolution in patterns of care.

Sections du résumé

OBJECTIVE OBJECTIVE
In this study we analyzed the impact of centralization on key metrics, outcomes and patterns of care at the Irish National Center.
SUMMARY BACKGROUND DATA BACKGROUND
Overall survival rates in esophageal cancer in the West have doubled in the last 25 years. An international trend towards centralization may be relevant, however this model remains controversial with Ireland, centralizing esophageal cancer surgery in 2011.
STUDY DESIGN METHODS
All patients (n=1245) with adenocarcinoma of the esophagus or junction treated with curative intent involving surgery, including endoscopic surgery, were included (n= 461 from 2000-2011, and 784 from 2012-2022). All data entry was prospectively recorded. Overall survival was measured (i) for the entire cohort; (ii) patients with locally advanced disease (cT2-3N0-3); and (iii) patients undergoing neoadjuvant therapy. All complications were recorded as per Esophageal Complication Consensus Group (ECCG) definitions, and the Clavien Dindo (CD) severity classification.
STATISTICAL ANALYSIS METHODS
Data were analyzed using GraphPad Prism (v.6.0) for Windows and SPSS (v.23.0) software (SPSS,Chicago,IL) RStudio (Rversion4.2.2). Survival times were calculated using log-rank test and a Cox-regression analysis, and Kaplan-Meier curves generated.
RESULTS RESULTS
Endotherapy for cT1a/IMC adenocarcinoma increased from 40 (9% total) to 245 (31% total) procedures between the pre-centralization (pre-C) and post-centralization (post-C) periods. A significantly (P<0.001) higher proportion of patients with cT2-3N0-3 disease in the post-C period underwent neoadjuvant therapy (66% vs 53%). Operative mortality was lower (P=0.02) post-C, at 2% vs 4.5%, and>IIIa CD major complications decreased from 33% to 25% (P<0.01). Recurrence rates were lower post-C (38% vs 53%, P<0.01). Median overall survival was 73.83 versus 47.23 months in the 2012-22 and 2000-11 cohorts respectively (P<0.001). For those who received neoadjuvant therapy, the median survival was 28.5 months pre-C and 42.5 months post-C (P<0.001).
CONCLUSION CONCLUSIONS
These data highlight improvements in both operative outcomes and survival from the time of centralization, and a major expansion of endoscopic surgery. Although not providing proof, the study suggests a positive impact of formal centralization with governance on key quality metrics, and an evolution in patterns of care.

Identifiants

pubmed: 39140599
doi: 10.1097/SLA.0000000000006487
pii: 00000658-990000000-01032
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest: None

Auteurs

Noel E Donlon (NE)

Trinity St. James's Cancer Institute, Dublin 8, Ireland.

Brendan Moran (B)

Trinity St. James's Cancer Institute, Dublin 8, Ireland.

Maria Davern (M)

Trinity St. James's Cancer Institute, Dublin 8, Ireland.

Matthew G Davey (MG)

Trinity St. James's Cancer Institute, Dublin 8, Ireland.

Czara Kennedy (C)

Trinity St. James's Cancer Institute, Dublin 8, Ireland.

Roisin Leahy (R)

Royal College of Surgeons, St Stephens Green, Dublin 2, Ireland.

Jenny Moore (J)

Trinity St. James's Cancer Institute, Dublin 8, Ireland.

Sinead King (S)

Trinity St. James's Cancer Institute, Dublin 8, Ireland.

Maeve Lowery (M)

Trinity St. James's Cancer Institute, Dublin 8, Ireland.

Moya Cunningham (M)

Trinity St. James's Cancer Institute, Dublin 8, Ireland.

Claire L Donohoe (CL)

Trinity St. James's Cancer Institute, Dublin 8, Ireland.

Dermot O'Toole (D)

Trinity St. James's Cancer Institute, Dublin 8, Ireland.

Narayanasamy Ravi (N)

Trinity St. James's Cancer Institute, Dublin 8, Ireland.

John V Reynolds (JV)

Trinity St. James's Cancer Institute, Dublin 8, Ireland.

Classifications MeSH